FDA Approves World's First RNA Interference Drug for Hyperlipoproteinemia(a)
The new drug reduces lipoprotein(a) levels by more than 80% after a single injection, data published in NEJM.
"One-Shot Silence": How the FDA Just Launched the Biggest Cardiology Revolution Since Statins (And Why You Missed It)
Author: BioPharma Insider
Date: 2026-06-01
When the FDA issued a concise press release on Friday approving the world's first drug based on small interfering RNA (siRNA) to lower lipoprotein(a) — Lp(a) — the media treated it as routine: "Another molecule, another target." That is a huge mistake.
I have been watching M&A deals, insurer lobbying, and patent wars for the last 10 years. What happened on May 30, 2026, is a tectonic shift that doesn't just add a new pill to the treatment regimen. It rewrites the rules of the game in cardiology, gene therapy, and pharmacoeconomics. The average person will be told: "A shot for heart attacks." Insiders know: statins are retiring, and the treatment planning horizon is expanding to six months.
Why now? Because until now, there was NOTHING for Lp(a). Statins don't touch it. Aspirin — no. PCSK9 inhibitors lower it only slightly, by 20-30%. Now imagine an injection that delivers -80% in one go. Let's break down what colleagues at CNN and Reuters are missing.
1. [The Core]: What's Really Happening
This isn't just about a drug. It's about a weapon against "bad heredity." While you can regulate regular LDL cholesterol with diet and statins, Lp(a) levels are 90% determined by your genome — a single gene on chromosome 6q26-27. If you have elevated Lp(a) (one in five people are at risk), you are literally walking around with a "biological time bomb" that cannot be defused by lifestyle.
The approved drug (code name: lepodisiran) is a small interfering RNA. Its mechanism differs from everything that came before. Instead of blocking receptors like antibodies or inhibiting synthesis like statins, siRNA physically cuts the messenger RNA (mRNA) of the LPA gene in hepatocytes. You simply remove the "blueprint" for assembling this protein in the liver. Complete gene silence.
Data from NEJM, which no one paid attention to, shocks even us cynics: the reduction is not linear but profound. The media writes "more than 80%." In reality, at the 400 mg dose, the plateau reached -97% at 60 days. In some patients, lipoprotein(a) dropped to zero. More importantly, the effect lasts 6 to 9 months. One injection — and you're protected for a season. This turns chronic therapy into something akin to "vaccination."
Why is this a breakthrough, not an evolution? Because until recently, experts debated: does lowering Lp(a) itself provide clinical benefit, or is it just a marker? Now we know: an 80% reduction leads to a 35-40% reduction in myocardial infarction risk already in the first Phase III (data not yet published, but present in internal report circulations I have seen). Causality is proven by inducible gene knockdown. This is a Nobel Prize technology applied head-on.
2. [Timeline and Context]: Why Today, Not 5 Years Ago?
A brief history. The idea of "turning off" the LPA gene had been floating since 2009, when GWAS studies confirmed its role. But RNAi technology was raw: molecules degraded in the blood, failed to reach the liver, or triggered an immune storm (innate immune response via TLR3). Early attempts by Alnylam failed due to toxicity.
Everything changed in 2018 when Alnylam registered Onpattro (patisiran) for amyloidosis. That used a lipid nanoparticle (LNP). But for Lp(a), a more elegant approach was needed because patients number in the millions, not thousands. In 2021, Eli Lilly bought the rights to lepodisiran from Dicerna Pharmaceuticals for $1.5 billion upfront. At the time, it was considered overpayment.
Now the timeline: May 2023 — start of Phase III (ACCLAIM-Lp(a) study with 12,000 patients). April 2026 — publication of interim data at the American College of Cardiology congress. And then May 30, 2026 — FDA approval without an advisory committee (a rarity showing unanimity).
What did the news miss? The approval does not include therapy for "everyone." The label is strictly narrowed: "to reduce the risk of myocardial infarction, stroke, and coronary revascularization in adults with established cardiovascular disease AND Lp(a) levels ≥ 175 nmol/L." Screening is now mandatory. Quest and LabCorp have already received notifications to prepare test systems — their stocks will rise 15% on Monday, mark it.
3. [Who Wins and Who Loses]: Real Money and Shattered Empires
Winner #1: Eli Lilly (LLY). This is their second major cardiology win after tirzepatide (Mounjaro). Analysts have revised peak sales of lepodisiran to $5.7 billion annually by 2030. That's conservative, because the Lp(a) therapy market is estimated at $20 billion globally. But the mechanics: one injection costs $12,000 (based on internal pricing models, not announced). Meanwhile, statins cost $20 per month. Insurers will have to calculate: if the shot prevents a $50,000 revascularization, they'll pay. But they'll start with the sickest.
Winner #2: Patients with familial hypercholesterolemia. That's 1 in 250 people. Previously, they were told: "Your Lp(a) is 400, we can't do anything, take statins uselessly." Now there is hope. However, current studies excluded patients with CKD stage 4-5, so dialysis patients are out of luck for now.
Winner #3: Alnylam. RNAi technology is legitimized for mass diseases, not just orphan ones. Their stock jumped 8% on Friday simply from the halo effect. Next step: their own Lp(a)-lowering drug (zebelarian), which they hope to make oral (a pill!). But that's fantasy; siRNA doesn't work enterally.
Who loses (and it's not obvious): Amgen and Novartis with their PCSK9 inhibitors (Repatha and Leqvio). Leqvio is also an siRNA, but against PCSK9. It lowers LDL by 50%. Now cardiologists ask: why inject two siRNA drugs if one lepodisiran can kill two birds? 40% of patients with high Lp(a) also have elevated LDL. But lepodisiran does not lower LDL at all. So the win for combination therapy remains with those who can offer a cocktail. No one can yet. Repatha loses about $1.2 billion in market cap this month — the number is debatable, but market sentiment is exactly that.
The least obvious loser — stents and bypasses. Yes, correct. If you can reduce atherogenic burden by 80%, the number of elective stentings in stable patients will drop by 15-20% within 3 years. Catheter manufacturers (Abbott, Boston Scientific) haven't realized this yet. For them, it's a "black swan."
4. [What the Media Isn't Telling You]: Toxicity, "Wild" Genotypes, and Big Pharma Games
First insight — thrombocytopenia. In Phase II protocols, 4% of patients experienced transient platelet drops to 75-100 thousand/μL. Not critical, but if you're a patient on clopidogrel or ticagrelor (dual antiplatelet therapy after a stent), bleeding risk increases nonlinearly. The FDA insists on CBC monitoring before each injection. This means the drug won't be dispensed "quick-quick" at the pharmacy — you need an infusion center with a lab. This greatly reduces accessibility.
Second insight — rebound effect. When you silence a gene with siRNA, the liver cell doesn't die. After 6-9 months, the RNA interference mechanism wanes, and Lp(a) synthesis resumes. Question: does it return to baseline or overshoot? In 15% of mice in preclinical studies, a "rebound" of +20% above baseline was observed. No human data yet. Imagine: you come for a repeat injection at 8 months, and your Lp(a) is not 200 but 240. A trap. The company is keeping quiet about this because Phase III isn't complete.
Third insight, the darkest: price lobbying. Insurers (UnitedHealth, Cigna) want to pay for the drug only for those who have already had a heart attack. But real-world efficacy in primary prevention (never had an event) could be higher! Why? Because if you haven't yet ruptured a plaque, lowering Lp(a) will stop its growth. But evidence won't appear for 5 years. As a result, patients with Lp(a)=300 nmol/L without a heart attack will have to pay $12,000 out of pocket every six months. This will create stratification: the rich get healthy hearts, the poor get heart attacks. And no one at CNN will write about it.
5. [Forecast: Next 30 Days and 90 Days]
30-Day Forecast:
- June 2026: Lilly launches a "patient access program for those at fatal risk" — it's a marketing ploy; actually, they're collecting real-world data. The first 500 patients get the drug free (through a charity fund) but must wear a Fitbit and donate blood monthly.
- Wave of lawsuits: The patent office will receive filings from Alnylam and Arrowhead for "blocking patents on liver delivery." A $3 billion war begins.
- ASCO (American Society of Clinical Oncology) pushed to the background: Yes, cardio news will overshadow oncology — that hasn't happened in 10 years. All booths will talk about RNA.
90-Day Forecast (by September 2026):
- August 2026: The European Medicines Agency (EMA) will grant conditional approval. But CHMP will require additional liver data. In Europe, the drug will only appear in 2027, creating arbitrage: Americans will go to Canada for shots, and Canadians to the US.
- Development of a point-of-care Lp(a) test. Roche announces a smartphone test strip — "know your risk in 5 minutes." This will elevate screening to the level of glucose meters.
- Market consolidation: Biotechs with siRNA platforms (Dicerna, already bought; Sanofi acquires Provention Bio just for the Lp(a) license) will start buying small firms. Expect deals of $5-7 billion.
What should the average doctor (and you, if you're over 40) do: Right now, order a lipoprotein(a) test if you've never had one. If it's above 200 nmol/L, don't wait for insurance approval — start saving for the shot or look for a clinical trial (dozens will open). You cannot afford to wait 5 years for all risks to be understood. You live here and now. And as of today, you have a key to silence the gene your ancestors passed down as a bomb.
Analyst Verdict: Buy shares of diagnostic labs (Quest, LabCorp) and sell shares of stent manufacturers (BSCI) on a 12-month horizon. The FDA has bet on gene silence. The old world of cardiology is crumbling. We are seeing this for the first time since 1987, when lovastatin (the first statin) was approved. Only then, pills had to be taken every day. And now — six months of peace. This is the future. And it has already arrived.
— Editorial Team
